Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 10, 2015, Pages 1285-1296

  Ferreira, Lívia Carvalho ^a,b   Arbab, Ali S ^c,e   Jardim Perassi, Bruna Victorasso ^b   Borin, Thaiz Ferraz ^b,d   Varma, Nadimpalli R S ^e   Iskander, A S M ^c,e   Shankar, Adarsh ^c,e   Ali, Meser M ^e   de Campos Zuccari, Debora Aparecida Pires ^b,d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Laboratório de Investigação Molecular no Câncer LIMC   (Brazil)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Department of Molecular Biology ^*  (Brazil)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

Angiogenesis; Breast neoplasm; Curcumin; SPECT; Xenograft model

Indexed keywords

ANGIOGENIC FACTOR; CURCUMIN; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CAPILLARY DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MTT ASSAY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CURCUMIN; FEMALE; HETEROGRAFTS; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84945352153     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150520093644     Document Type: Article

References (71)

1. Hicks, D.G.; Kulkarni, S. Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate human epidermal growth factor receptor 2 testing. Arch. Pathol. Lab Med., 2008, 132(6), 1008- 1015.
2. Park, S.Y.; Jang, W.J.; Yi, E.Y.; Jang, J.Y.; Jung, Y.; Jeong, J.W.; Kim, Y.J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J. Pineal. Res., 2010, 48 (2), 178-84.
3. Patenaude, A.; Parker, J.; Karsan, A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc. Res., 2010, 79 (3), 217-223
4. El Hallani, S.; Boisselier, B.; Peglion, F.; Rousseau, A.; Colin, C.; Idbaih, A.; Marie, Y.; Mokhtari, K.; Thomas, J.L.; Eichmann, A.; Delattre, J.Y.; Maniotis, A.J.; Sanson, M. A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain, 2010, 133(Pt 4), 973-982.
5. Yu, H.B.; Zhang, H.F.; Zhang, X.; Li, D.Y.; Xue, H.Z.; Pan, C.E.; Zhao, S.H. Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Hepatogastroenterology, 2010, 57(102-103), 1241-1246
6. Arbab, A.S. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol. Histopathol., 2012, 27 (5), 549-557.
7. Hajrasouliha, A.R.; Funaki, T.; Sadrai, Z.; Hattori, T.; Chauhan, S.K.; Dana, R. Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci., 2012, 53(3), 1244-1250.
8. Lee, T.H.; Seng, S.; Sekine, M.; Hinton, C.; Fu, Y.; Avraham, H. K.; Avraham, S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med., 2007, 4(6), e186
9. Hillen, F.; Griffioen, A.W. Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis. Rev., 2007, 26(3-4), 489-502
10. Yu, H.; Mohan, S.; Natarajan, M. Radiation-Triggered NF-κB activation is responsible for the angiogenic signaling pathway and neovascularization for breast cancer cell proliferation and growth. Breast Cancer (Auckl) 2012, 6, 125-135.
11. Dang, C.V.; Semenza, G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci., 1999, 24(2), 68-72.
12. Semenza, G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol. Med., 2002, 8(4 Suppl), S62-S67
13. Kallergi, G.; Markomanolaki, H.; Giannoukaraki, V.; Papadaki, M. A.; Strati, A.; Lianidou, E.S.; Georgoulias, V.; Mavroudis, D.; Agelaki, S. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res., 2009, 11(6), R84
14. Vordermark, D. Hypoxia-specific targets in cancer therapy: Role of splice variants. BMC Med., 2010, 8, 45.
15. Greenberg, S.; Rugo, H.S. Triple-negative breast cancer: Role of antiangiogenic agents. Cancer J., 2010, 16(1), 33-38
16. Delli Carpini, J.; Carpini, J.D.; Karam, A.K.; Montgomery, L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis, 2010, 13(1), 43-58
17. Shibuya, M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Gen. Cancer, 2011, 2(12), 1097-1105.
18. Mito, S.; Watanabe, K.; Harima, M.; Thandavarayan, R.A.; Veeraveedu, P.T.; Sukumaran, V.; Suzuki, K.; Kodama, M.; Aizawa, Y. Curcumin ameliorates cardiac inflammation in rats with autoimmune myocarditis. Biol. Pharm. Bull., 2011, 34(7), 974-979.
19. Patel, B.B.; Majumdar, A.P. Synergistic role of curcumin with current therapeutics in colorectal cancer: Minireview. Nut. Cancer, 2009, 61(6), 842-846
20. Villegas, I.; Sánchez-Fidalgo, S.; Alarcón de la Lastra, C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol. Nutr. Food Res., 2008, 52(9), 1040-1061
21. Chakravarti, N.; Kadara, H.; Yoon, D.J.; Shay, J. W.; Myers, J.N.; Lotan, D.; Sonenberg, N.; Lotan, R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev. Res. (Phila), 2010, 3(3), 331-338
22. Fossey, S.L.; Bear, M.D.; Lin, J.; Li, C.; Schwartz, E.B.; Li, P.K.; Fuchs, J.R.; Fenger, J.; Kisseberth, W.C.; London, C.A. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer, 2011, 11, 112.
23. Zubair, A.; Frieri, M. Role of nuclear factor-ĸB in breast and colorectal cancer. Curr. Aller. Asthma Rep., 2013, 13(1), 44-49.
24. Chang, A.A.; Van Waes, C. Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma. Adv. Otorhinolaryngol, 2005, 62, 92-102
25. Olivera, A.; Moore, T.W.; Hu, F.; Brown, A.P.; Sun, A.; Liotta, D.C.; Snyder, J. P.; Yoon, Y.; Shim, H.; Marcus, A. I.; Miller, A. H.; Pace, T.W. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int. Immunopharmacol., 2012, 12(2), 368-377.
26. Shan, B.; Schaaf, C.; Schmidt, A.; Lucia, K.; Buchfelder, M.; Losa, M.; Kuhlen, D.; Kreutzer, J.; Perone, M.J.; Arzt, E.; Stalla, G.K.; Renner, U. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J. Endocrinol., 2012, 214(3), 389- 398.
27. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc., 2008, 3(6), 1101-1108.
28. Jardim-Perassi, B.V.; Arbab, A.S.; Ferreira, L.C.; Borin, T.F.; Varma, N.R.; Iskander, A.S.; Shankar, A.; Ali, M.M.; De Campos Zuccari, D.A. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoSOne, 2014, 9 (1), e85311.
29. Jensen, M.M.; Jørgensen, J.T.; Binderup, T.; Kjaer, A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDGmicroPET or external caliper. BMC Med. Imag., 2008, 8, 16.
30. Kunnumakkara, A.B.; Anand, P.; Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett., 2008, 269(2), 199-225
31. Yadav, V.R.; Aggarwal, B.B. Curcumin: A component of the golden spice, targets multiple angiogenic pathways. Cancer Biol. Ther., 2011, 11 (2), 236-241.
32. Chan, D.A.; Kawahara, T.L.; Sutphin, P.D.; Chang, H.Y.; Chi, J. T.; Giaccia, A.J. Tumor vasculature is regulated by PHD2- mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell, 2009, 15(6), 527-538.
33. Yang, C.L.; Liu, Y.Y.; Ma, Y.G.; Xue, Y.X.; Liu, D.G.; Ren, Y.; Liu, X.B.; Li, Y.; Li, Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoSOne, 2012, 7(5), e37960.
34. Singh, S.; Khar, A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med. Chem., 2006, 6(3), 259-270.
35. Shishodia, S.; Amin, H.M.; Lai, R.; Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol., 2005, 70(5), 700- 713
36. Park, W.; Amin, A.R.; Chen, Z.G.; Shin, D.M. New perspectives of curcumin in cancer prevention. Cancer Prev. Res. (Phila), 2013, 6(5), 387-400.
37. Jiang, M.; Huang, O.; Zhang, X.; Xie, Z.; Shen, A.; Liu, H.; Geng, M.; Shen, K. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules, 2013, 18(1), 701-720
38. Thakkar, A.; Sutaria, D.; Grandhi, B.K.; Wang, J.; Prabhu, S. The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol. Rep., 2013, 29(4), 1671-1677.
39. Cai, Y.Y.; Lin, W. P.; Li, A.P.; Xu, J.Y. Combined effects of curcumin and triptolide on an ovarian cancer cell line. Asi. Pac. J. Cancer Prev., 2013, 14(7), 4267-4271.
40. Palange, A.L.; Di Mascolo, D.; Singh, J.; De Franceschi, M.S.; Carallo, C.; Gnasso, A.; Decuzzi, P. Modulating the vascular behavior of metastatic breast cancer cells by curcumin treatment. Front. Oncol., 2012, 2, 161.
41. Shahani, K.; Swaminathan, S.K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res., 2010, 70 (11), 4443-4452.
42. Lee, S.J.; Krauthauser, C.; Maduskuie, V.; Fawcett, P.T.; Olson, J. M.; Rajasekaran, S.A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer, 2011, 11, 144.
43. Kunnumakkara, A.B.; Guha, S.; Krishnan, S.; Diagaradjane, P.; Gelovani, J.; Aggarwal, B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res., 2007, 67(8), 3853-3861.
44. Bhadada, S.V.; Goyal, B.R.; Patel, M.M. Angiogenic targets for potential disorders. Fundam. Clin. Pharmacol., 2011, 25(1), 29-47.
45. Wang, C.A.; Jedlicka, P.; Patrick, A.N.; Micalizzi, D.S.; Lemmer, K.C.; Deitsch, E.; Casás-Selves, M.; Harrell, J.C.; Ford, H.L. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J. Clin. Invest., 2012, 122(5), 1895-1906.
46. Ali, M.M.; Janic, B.; Babajani-Feremi, A.; Varma, N.R.; Iskander, A.S.; Anagli, J.; Arbab, A.S. Changes in vascular permeability and expression of different angiogenic factors following antiangiogenic treatment in rat glioma. PLoSOne, 2010, 5(1), e8727
47. Blankenberg, F.G.; Backer, M.V.; Levashova, Z.; Patel, V.; Backer, J.M. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur. J. Nucl. Med. Mol. Imag., 2006, 33(7), 841-848
48. Blankenberg, F. G.; Levashova, Z.; Sarkar, S. K.; Pizzonia, J.; Backer, M.V.; Backer, J.M. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: A molecular imaging study. Transl. Oncol., 2010, 3(1), 56-64.
49. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438(7070), 967-974.
50. Chen, C.; Huang, X.; Cai, H.; Xu, J. Anti-proliferation and antiangiogenesis of curcumin-K30 solid dispersion. Zhong. Nan. Da. Xue Xue. Bao. Yi. Xue. Ban., 2010, 35(10), 1029-1036.
51. Yoysungnoen, P.; Wirachwong, P.; Bhattarakosol, P.; Niimi, H.; Patumraj, S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cellimplanted nude mice. Clin. Hemorheol. Microcirc., 2006, 34(1-2), 109-115.
52. Chakraborty, G.; Jain, S.; Kale, S.; Raja, R.; Kumar, S.; Mishra, R.; Kundu, G.C. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol. Med. Rep., 2008, 1(5), 641-646.
53. Bian, F.; Zhang, M.C.; Zhu, Y. Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. Ophthalmologica, 2008, 222(3), 178-186.
54. Andrzejewski, T.; Deeb, D.; Gao, X.; Danyluk, A.; Arbab, A.S.; Dulchavsky, S.A.; Gautam, S.C. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res., 2008, 17(6), 257-267.
55. Mauceri, H.J.; Seetharam, S.; Beckett, M.A.; Lee, J.Y.; Gupta, V. K.; Gately, S.; Stack, M.S.; Brown, C.K.; Swedberg, K.; Kufe, D. W.; Weichselbaum, R.R. Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int. J. Cancer, 2002, 97(4), 410-415
56. Szarvas, T.; Jäger, T.; Laszlo, V.; Kramer, G.; Klingler, H.C.; vom Dorp, F.; Romics, I.; Ergün, S.; Rübben, H. Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer. Urology, 2012, 80(3), 737.e13-8.
57. Volm, M.; Mattern, J.; Koomägi, R. Angiostatin expression in nonsmall cell lung cancer. Clin. Cancer Res., 2000, 6(8), 3236-3240
58. Yabushita, H.; Noguchi, M.; Kinoshita, S.; Kishida, T.; Sawaguchi, K. Angiostatin expression in endometrial cancer. Oncol. Rep., 2002, 9(6), 1193-1196
59. Yabushita, H.; Noguchi, M.; Obayashi, Y.; Kishida, T.; Noguchi, Y.; Sawaguchi, K. Angiostatin expression in ovarian cancer. Oncol. Rep., 2003, 10 (5), 1225-1230.
60. Gupta, A.; Zhou, C.Q.; Chellaiah, M.A. Osteopontin and MMP9: Associations with VEGF expression/secretion and angiogenesis in PC3 prostate cancer cells. Cancers (Basel), 2013, 5(2), 617-638.
61. Gururaj, A.E.; Belakavadi, M.; Venkatesh, D.A.; Marmé, D.; Salimath, B.P. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem. Biophys. Res. Commun., 2002, 297(4), 934- 942.
62. De Palma, M.; Naldini, L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res., 2011, 17(16), 5226-5232.
63. Yancopoulos, G.D. Clinical application of therapies targeting VEGF. Cell, 2010, 143(1), 13-16.
64. Fiedler, U.; Scharpfenecker, M.; Koidl, S.; Hegen, A.; Grunow, V.; Schmidt, J.M.; Kriz, W.; Thurston, G.; Augustin, H.G. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood, 2004, 103(11), 4150-4156
65. Hegen, A.; Koidl, S.; Weindel, K.; Marmé, D.; Augustin, H.G.; Fiedler, U. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler. Thromb. Vasc. Biol., 2004, 24(10), 1803-1809.
66. Maisonpierre, P.C.; Suri, C.; Jones, P.F.; Bartunkova, S.; Wiegand, S.J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T.H.; Papadopoulos, N.; Daly, T.J.; Davis, S.; Sato, T.N.; Yancopoulos, G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 1997, 277(5322), 55-60.
67. Ji, C.; Cao, C.; Lu, S.; Kivlin, R.; Amaral, A.; Kouttab, N.; Yang, H.; Chu, W.; Bi, Z.; Di, W.; Wan, Y. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother. Pharmacol., 2008, 62(5), 857-865.
68. Cheng, T.S.; Chen, W.C.; Lin, Y.Y.; Tsai, C.H.; Liao, C.I.; Shyu, H.Y.; Ko, C.J.; Tzeng, S.F.; Huang, C.Y.; Yang, P.C.; Hsiao, P. W.; Lee, M.S. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis. Cancer Prev. Res. (Phila), 2013, 6 (5), 495-505.
69. Nagaraju, G.P.; Aliya, S.; Zafar, S.F.; Basha, R.; Diaz, R.; El- Rayes, B.F. The impact of curcumin on breast cancer. Integr. Biol. (Camb), 2012, 4(9), 996-1007.
70. Matés, J.M.; Segura, J.A.; Alonso, F.J.; Márquez, J. Natural antioxidants: Therapeutic prospects for cancer and neurological diseases. Mini. Rev. Med. Chem., 2009, 9(10), 1202-1214.
71. Mukherjee, S.; Mazumdar, M.; Chakraborty, S.; Manna, A.; Saha, S.; Khan, P.; Bhattacharjee, P.; Guha, D.; Adhikary, A.; Mukhjerjee, S.; Das, T. Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/beta-catenin negative feedback loop. Stem Cell Res. Ther., 2014, 5(5), 116.